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Background: Chronic obstructive pulmonary disease (COPD) is a respiratory condition characterised by dyspnoea,
excessive sputum production, chronic cough, bronchitis and emphysema. Functionally, exercise tolerance is poor
for people with COPD and is linked to difficulty in performing daily tasks. More specifically, exercise difficulties are
due partly to dyspnoea and lower limb skeletal muscle dysfunction. The benefit of exercise that does not
exacerbate the disease while improving exercise tolerance is salient. Whole-body vibration (WBV) is a mode of
physical activity known to improve muscular function of the lower limbs, yet efficacy has not been investigated for
a WBV intervention conducted in a home-based setting for people with COPD.
Methods/design: This clinically registered trial is a non-randomised placebo cross-over intervention based in the
home of each participant (ACTRN12612000508875). Participants diagnosed with COPD will complete a six-week
WBV intervention and then after a two-week washout period, will complete a six-week placebo training
intervention. Participants will complete sessions twice a week. The duration of the trial is 14 weeks.
Community-dwelling older adults with COPD will provide informed voluntary consent to participate. Outcome
measures will include immediate, acute, and long-term responses to exercise.
Discussion: Quantifying responses to WBV among people with COPD will allow discussion of efficacy of WBV as a
mode of physical activity. The skill required by the participant to perform physical activity with WBV is not
demanding and may enhance habitual sustainability. The results of this trial could be used to support further
research in both clinical and community settings.
Trial registration: Australian New Zealand Clinical Trials Registry (ANZCTR12612000508875)
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The World Health Organisation’s (WHO) current defin-
ition of chronic obstructive pulmonary disease (COPD)
is a lung ailment fundamentally characterised by persist-
ent blockage of airflow from the lungs [1]. In 2004 the
WHO estimated 64 million global cases of COPD and
later predicted COPD to become the third leading cause* Correspondence: trentham.furness@monash.edu
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reproduction in any medium, provided the orof death by 2030 [2]. Among Australians, COPD was the
third leading cause of burden of disease and injury be-
hind ischaemic heart disease and stroke [3]. Somewhat
understandably, tobacco usage was listed with physical
inactivity as the two leading risk factors eliciting burden
of disease in Australia [3]. Although not always the case,
tobacco smoke is the leading risk factor for COPD [4].
While the cost of COPD in Australia has not been dir-
ectly estimated, respiratory disease alone accounted for
AU$3.31 billon (6.3%) of the total allocated health ex-
penditure in Australia [5].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to supply the body with oxygen, most modes of physical
activity lead to breathlessness if the disease is pro-
gressed. Perceived breathlessness, or dyspnoea, leads to
physical inactivity and consequently compounds the risk
of burden of disease to those individuals. As a counter-
active strategy, physical activity is routinely incorporated
to the management of stable COPD [6].
Recommendations from the WHO, the American
Thoracic Society, the European Respiratory Society and
the Thoracic Society of Australia and New Zealand, and
other professional bodies support physical activity as in-
tegral to pulmonary rehabilitation programs in public
heath settings to assist individuals affected by COPD [6].
A goal of physical activity within pulmonary rehabilita-
tion is to improve exercise tolerance for people with
COPD. During physical activity, the cardiovascular and
neuromuscular systems are stressed above resting levels,
which if continued over time, can improve systemic
responses. Specifically, an improvement of cardiac out-
put and cellular respiration are common after physical
activity interventions [7]. Improvement in exercise toler-
ance has functional benefit such as the increased ability
to complete activities of daily living (ADLs).
Maintenance and improvement of ADLs is central for
functional independence [6,8]. Given that functional in-
dependence can rely on the ability to complete ADLs,
muscular strength, muscular power and gait ability are
considered important. Activities requiring strong and
powerful muscular contraction are fundamental and in-
clude rising from a chair, climbing stairs, turning and
adjusting posture, and stumbling to avoid a fall. People
with COPD have less muscular strength and power than
healthy age matched controls [9]. Subsequently, this
population may have poorer exercise tolerance asso-
ciated with muscular weakness [10]. As such, for people
with COPD, muscular deconditioning/dysfunction is
postulated to lead to poor performance of ADLs and
poor exercise tolerance.
A primary objective of pulmonary rehabilitation is to
combat poor muscular performance. The components of
pulmonary rehabilitation vary, but include physical activity
(both aerobic conditioning and resistance training),
healthy lifestyle education, and nutrition counselling [11].
Initially, pulmonary rehabilitation can be implemented at
an outpatient setting, usually followed by a home-based
intervention that relies mostly on the compliance of the
patient. Efficacy was established after systematic review of
both outpatient pulmonary rehabilitation [12-14] and
home-based pulmonary rehabilitation [15-17].
During pulmonary rehabilitation, aerobic conditioning
was most effective in improving exercise tolerance at in-
tensities over 50% of peak oxygen consumption (VO2peak)
[11,18]. Although resistance training improved muscularstrength [19], muscular power [20] and variables of gait
[21], dedicated strategies for resistance training of the
lower limbs lack thorough condition specific recommen-
dation for people with COPD. A recent literature review
of resistance training during peripheral muscle training
reported the efficacy of resistance training for people with
COPD [8]. As such, resistance training of the lower limbs
elicited appreciable gains in muscular strength for people
with COPD that may carry over to performance of some
ADLs [8]. However, resistance training was conducted in
conjunction with other modes of physical activity such as
aerobic conditioning. The independent effect of resistance
training therefore, could not be established.
Considering the statistical and scientific evidence for
efficacy of physical activity to reduce burden of disease,
the need for safe and valid exercise interventions for
people with COPD is salient. The common modes of
physical activity; aerobic conditioning and resistance
training can exacerbate the disease and affect program
compliance [22,23] and may lead to reduced physical ac-
tivity because of fear of breathlessness. The clinical and
social merit of physical activity that can minimise dys-
pnoea may provide additional exercise tolerance benefit
for people with COPD. Whole-body vibration may be
such a mode of physical activity, and can be easily com-
pleted in the home with little skill demand.
Whole-body vibration is a mode of physical activity
during which an individual stands on a vibration plat-
form that can create acceleration predominantly in the
vertical (Fz) direction. The accelerations are transmitted
to the body and postulated to elicit physiological
responses similar to other modes of physical activity
such as aerobic conditioning and resistance training.
After WBV, increased leg muscular strength and mus-
cular power [24,25], oxygen consumption [26,27],
growth hormone, and testosterone levels [24,28] were
reported in healthy young and older adult populations.
Furthermore, WBV may be a safe and effective mode of
physical activity to improve muscular strength, body bal-
ance and mechanical competence of bone for older
adults with low bone mineral density [29,30]. A growing
body of literature on the impact of WBV has included
sub-optimal health populations such as cystic fibrosis
[31], multiple sclerosis [32] and stroke [33]. Yet to date,
well conducted trials into the efficacy of WBV in
patients with COPD are scarce in the literature.
One paper has been published to investigate efficacy
of WBV to improve muscular strength and muscular
power of people with COPD. In conjunction with a clin-
ically based three-week pulmonary rehabilitation inter-
vention, WBV may have enhanced exercise tolerance
[34]. The authors suggested that long-term studies are
needed to determine optimal intensity and duration of
WBV for people with COPD, though WBV seemed to be
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ever, efficacy of a standalone WBV intervention remains
unknown in outpatient and home-based settings.
Objective
The objective of the trial is to advance knowledge of
effects of physical activity on exercise tolerance and
functional performance of the lower limbs of people
with COPD, and to test the efficacy of a WBV interven-
tion to beneficially effect exercise tolerance and func-
tional performance of the lower limbs without causing
exacerbations. The intervention will be conducted and
data collected in the home of each participant.
Methods/design
This trial will be conducted as a non-randomised inter-
vention with crossover to placebo. Given the nature of
COPD, and exacerbations expected of it, this trial will be
a phase II efficacy trial and as such will not be con-
ducted as a randomised controlled trial. People with
stable COPD will be invited to participate. It is necessary
to first conduct the WBV intervention, and then the
PLACEBO intervention in an effort to maximise partici-
pant numbers in the WBV group, with anticipated drop-
out over the course of the 14-week intervention. A
control condition could compromise trial compliance
and randomisation is not critical to an efficacy trial.
Participants and recruitment
Community-dwelling patients listed on the Department of
Respiratory and Sleep Medicine, Monash Medical Centre,
Southern Health data-base will be contacted to procure
interest in participation and later provide informed volun-
tary consent. Participants must be over 40 years of age, be
fully independent in residence, and have well-managed,
stable Stage II COPD according to the Global initiative for
chronic Obstructive Lung Disease (GOLD) criteria. A con-
venient sample of people with stable Stage II COPD will be
targeted due to a reduced chance of participant dropout
from exacerbations independent of the 14-week interven-
tion. Participants must be free of contraindicators to phys-
ical activity as well as contraindicators to WBV (free of self
reported; vascular disease, reactive arthritis, vertigo, and risk
of thromboembolism [28,35,36]. The trial has the ethical
approval of the Monash Medical Centre, Southern Health
Human Research Ethics Committee A and the Australian
Catholic University Human Research Ethics Committee.
The trial is registered with the Australian New Zealand
Clinical Trials Registry (ACTRN12612000508875).
Interventions
Across the 14-week duration of the trial, participants
will be first allocated to a six-week WBV intervention, atwo-week washout period [37], and a six-week PLA-
CEBO intervention.WBV intervention
The WBV intervention will consist 12 WBV sessions
over a consecutive six-week period. The participants will
complete two vibration sessions per week separated by
at least 48 hours. Efficacy of session frequency had been
previously established for healthy community-dwelling
older adults [25]. A WBV session will consist of five,
60 second vibration bouts, interspersed with 60 seconds
of passive rest. Although the most effective protocol is
yet to be established, the selected protocol had been
used previously to establish efficacy of WBV interven-
tions [36,38,39]. During rest, the participant will remain
on the vibration platform and will be encouraged to
stand with a posture that resembles the ‘anatomical pos-
ition’. More specifically, the participant assumes a stand-
ing position with the feet together, the arms to the side,
and the head, eyes and palms facing forwards. The fore-
arms are supinated.
A side alternating vibration platform (Amazing Super
Health, Melbourne, AUS) will be used. For each vibra-
tion bout, platform frequency will be 25 Hz, peak-to-
peak displacement 2.0 mm, peak acceleration ~24.67 m.
s-2, and gravitational force ~2.52 g. The WBV intensity
was chosen to reduce the risk of fracture to fragile bones
[40] and potential for other injury [41]. The vibration
platform peak-to-peak displacement and frequency were
validated prior to this proposal in an unpublished pilot
study. Foot placement (second toe) will be equidistant,
20 cm from axis of rotation. The participant will wear
flat soled shoes. Skidding will be checked according to
the recommended method of the International Society
of Musculoskeletal and Neuronal Interactions. A piece
of paper will be placed under the foot during a vibration
bout to ensure constant contact with the vibration plat-
form [42]. The participant will be required to stand with
~20º knee flexion to allow transmission of vibration
about the lower limbs [43]. Knee angle will be filmed,
and later quantified across the intervention for each
participant.PLACEBO intervention
A prototype vibration platform will be used for the PLA-
CEBO intervention. For each vibration bout, platform
frequency will be 25 Hz, peak-to-peak displacement
~0.0 mm, peak acceleration ~0.00 m.s-2, and gravita-
tional force ~0.0 g (cognisant that the Earth’s gravita-
tional force is constant 1.0 g). Participants will be
required to follow the same procedure of the WBV
intervention. Participants will be told the PLACEBO
intervention is an “ultra-low frequency” vibration
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tioned WBV intervention.
Outcome measures
Reliability of outcome measures will be established over
a test-retest-retest protocol. Exercise tolerance variables
will be immediate responses to WBV; (1) perceived dys-
pnoea quantified with the Borg CR-10 visual analogue
scale, (2) heart rate, and (3) saturation of haemoglobin.
Functional performance variables will be simulated
ADLs and kinematic markers of gait; (1) the 5-chair
stands test, (2) the timed up and go test, (3) stride
length, (4) stride time, and (5) stride velocity. Data will
be collected at baseline and subsequent fortnight for
14 weeks. Data of all dependent variables will be col-
lected to quantify at least one of three different data
classifications: (1) immediate, (2) acute, and (3) long-
term. Immediate perceived dyspnoea, heart rate, and sat-
uration of haemoglobin will be collected during the final
WBV or PLACEBO bout (after 30 seconds of the 60 sec-
ond bout). Acute kinematic markers of gait will be col-
lected within two minutes of a completed WBV or
PLACEBO bout [38,44]. Long-term simulated ADLs and
kinematic markers of gait will be collected at least
48 hours after a WBV or PLACEBO bout [25,45].
To complete the 5-chair stands test the participant is
asked to sit in a standard height (46 cm, including back
rest) chair with arms folded across the chest. The par-
ticipant is then asked to stand and sit five times [35,46].
To complete the timed up and go test, the participant
is asked to sit in a standard height (46 cm) arm (63 cm)
chair. The participant is then asked to stand, walk three
metres to a marker on the floor, turn, return, and sit on
the chair [46,47].
Kinematic markers of gait will be quantified with the
GAITRiteW electronic walkway (CIR Systems Inc,
Peekskill, USA). Participants will be instructed to walk
at a self-selected comfortable speed along a straight,
flat, and even walkway area containing the mat. Body
length is measured from the base of the foot (unshod)
to the crown of the head while standing in the anatom-
ical position. During data collection, participants will
walk (shod) over the mat five times in a discontinuous
process with an approach and departure distance equal to
two body lengths. The procedure was reliable for step
length, step time, and velocity among older woman (ICC
range 0.860 to 0.940; mean age = 68 years) [48].
Sample size
It is expected that WBV will not change dyspnoea from
baseline. To allow sample size calculation therefore, data
of functional performance variables were considered pri-
mary and used to estimate sample size. The selected
dependent variables were sourced from a previous studyof WBV and healthy community-dwelling older adults
[25]. Sample size needed for a one tailed paired t-test
with α 0.05 and n = 14 with power = 0.90 was n =16 for
the 5 chair stands test n < 10 for the timed up and go
test. To allow for an anticipated participant drop out of
at least 20%, a total of 20 participants will be included in
the study.Discussion
Whole-body vibration is a mode of physical activity
thought to affect the musculoskeletal, endocrine and car-
diovascular systems of the human body. Researchers can
choose to use several platform types, a range of vibration
frequencies, peak-to-peak displacements and a multitude
of stance postures to affect dependent variables. As such,
both effective and ineffective results from WBV have
been reported. However, negative effects of WBV are
rarely reported when vibration platforms and protocols
are matched to a specific population [49]. Considering
the growing WBV literature base, it is an oversight that
prescription guidelines for safe and effective WBV have
not been established, despite increasing existence of vi-
bration platforms in the health and fitness industry.
However, since many variables of a WBV intervention
can be manipulated, comparison among studies and sub-
sequent guideline recommendations are difficult.
Although WBV has rarely been used as an exercise
intervention for people with sub-optimal health, condi-
tion specific exercise is possible. Whole-body vibration
had limited use as an exercise intervention for people
with COPD. However, from the paucity of available lit-
erature base on sub-optimal health samples, WBV
exacerbations are rarely described, but may lack full
disclosure.
A WBV intervention should be safe and valid before
implemented to a sample cohort, regardless of health
status. Encouragingly, WBV did not negatively affect
people with stable COPD [34], people with cystic fibrosis
[31] or heart transplant recipients [50]. Despite current
knowledge of WBV, as a standalone home-based mode
of physical activity, efficacy has not been established for
improvement or maintenance of exercise tolerance and
functional performance of the lower limbs of people
with COPD. Furthermore, it is unknown if a long-term
WBV intervention will elicit exacerbations of COPD, or
be well tolerated and complied by people with COPD.
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